Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy (NCT06712407)
An Open-label Study to Assess the Efficacy and Safety of Extended TARPEYO® (Delayed-release Budesonide Capsules) Treatment in Adult Patients With Primary IgA Nephropathy Who Have Completed 9 Months of TARPEYO® 16 mg Once Daily Treatment in Real-world Clinical Practice
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is: Is there a treatment benefit of TARPEYO® 16 mg QD extended use? Participants will * take part in this study for about 19 months * Have urine tests done * Have blood samples taken * Have physical examinations done
Who can join: Review the eligibility criteria below.
Location: Univ of Alabama/Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (38 Sites)
Showing the first 25 of 38 sites.
- Univ of Alabama/Birmingham — Birmingham, Alabama
- Arizona Kidney Disease & Hypertension Centers (AKDHC) — Glendale, Arizona
- The Medical Research Group, Inc. — Fresno, California
- UCI Health-UCI Medical Center — Orange, California
- Loma Linda University — San Bernardino, California
- UCSF Health-UCSF Medical Center-Parnassus - Nephrology and Hypertension Faculty Practice — San Francisco, California
- Stanford University — Stanford, California
- University of Colorado Hospital (UCH) - Kidney Disease and Hypertension Clinic - Anschutz Medical Campus Location — Aurora, Colorado
- Yale University Nephrology Clinical Trials Program — New Haven, Connecticut
- Florida Kidney Physicians — Boca Raton, Florida
- Central Florida Kidney Specialists — Orlando, Florida
- Southeastern Clinical Research Institute, LLC — Augusta, Georgia
- Cobb Nephrology Hypertension Associates, PC — Austell, Georgia
- Georgia Nephrology — Lawrenceville, Georgia
- University of Louisville — Louisville, Kentucky
- Ochsner Health, New Orleans — New Orleans, Louisiana
- University of Maryland Division of Nephrology — Baltimore, Maryland
- Boston Medical Center; Boston University Chobanian & Avedisian School of Medicine — Boston, Massachusetts
- University of Minnesota Health Fairview — Minneapolis, Minnesota
- Washington University in St. Louis — St Louis, Missouri
- University of New Mexico — Albuquerque, New Mexico
- Renal Medical Associates — Albuquerque, New Mexico
- New York Nephrology Vasculitis and Glomerular Center — Clifton Park, New York
- Chinatown Kidney Care, PLLC — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
📞 Contact the Study Coordinator
Phone: (844) 442-0011
Email: medical.information@calliditas.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in IgA Nephropathy
- A Study of Zigakibart in Adults With IgA Nephropathy — Birmingham, Alabama
- Atrasentan in Patients With IgA Nephropathy — Birmingham, Alabama
- Atrasentan in Patients With Proteinuric Glomerular Diseases — Glendale, California
- Atacicept in Subjects With IgA Nephropathy — Brisbane, California
- A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G — Lawrenceville, Georgia
- Study of BHV-1400 in IgA Nephropathy — Farmington, Connecticut
Explore by condition: All IgA Nephropathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.